Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2005 Sep;6(9):962-8.

BG-9928 (Biogen Idec).

Author information

1
Division of Health Practice, Auckland University of Technology-Akoranga Campus, Auckland, New Zealand. sdoggrell@xtra.co.nz

Abstract

Biogen Idec, under license from CV Therapeutics, is developing BG-9928, a selective oral adenosine A, receptor antagonist, for the potential treatment of congestive heart failure. By January 2003, phase II trials of BG-9928 were ongoing.

PMID:
16187697
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center